Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
Work
Year: 2018
Type: article
Abstract: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safet... more
Source: Thyroid
Institutions University of Ulsan, Asan Medical Center, Ulsan College, Samsung Medical Center, Sungkyunkwan University +6 more
Cites: 26
Cited by: 49
Related to: 10
FWCI: 5.86
Citation percentile (by year/subfield): 91.75
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: green